Home Blog Page 1342

X-Design Takes #1 on Product Hunt with AI Agent That Democratizes Branding for Local Businesses

SYDNEY, Dec. 4, 2025 /PRNewswire/ — X-Design, the AI branding platform built specifically for the brick-and-mortar economy, today announced it has achieved the #1 Product of the Day on Product Hunt. This milestone marks the launch of its new AI Agent, an autonomous design partner that enables cafés, fitness studios, and service providers to build and maintain a consistent, professional brand identity in minutes.

While many AI tools focus on isolated tasks, X-Design’s AI Agent creates a unified workflow powered by long-term contextual memory. It serves as an always-on brand manager, ensuring that everything from a shop’s logo to its Instagram posts retains the brand’s unique “Visual DNA” without requiring users to repeat themselves.

Solving the “Visual Consistency” Struggle for SMBs
Built on insights from over 500 beta users in retail, F&B, and wellness sectors, the Agent addresses the biggest challenge for small businesses: fragmentation. “Small business owners wear every hat, but ‘Chief Design Officer’ shouldn’t have to be one of them,” said Elvis, Founder of X-Design. “Reaching No. 1 on Product Hunt validates our belief that branding should be accessible to everyone. We aren’t just generating logos; we are giving local shops a partner that remembers their specific style, tone, and preferences, effectively eliminating the need to ‘brief’ the designer every time they need a new asset.”

Key Capabilities Powering the Win
1. A Full Brand System in Under 10 Minutes
Instead of piecing together designs from different tools, users can chat with the AI Agent to generate a complete identity system, including unique logos, color palettes, and typography, in a single conversation. The AI instantly visualizes these elements on real-world mockups like storefront signage and packaging. In beta testing, this streamlined workflow allowed 92% of users to finalize a production-ready brand identity within just 10 minutes.
2. The “Always-On” Brand Manager
Once a brand is established, the Agent automatically saves all assets into a dynamic Brand Kit. This ensures that when a user requests a new asset, such as a holiday promo poster or a menu update, the system generates designs that strictly follow the stored brand guidelines without needing fresh instructions. This automated consistency helped beta users achieve 35% higher visual coherence across their marketing materials.
3. Real-World Ready Output
Addressing the specific needs of physical businesses, the Agent produces files formatted for both digital screens and physical print. Whether users need menus, flyers, event signage, or promo cards, the output supports high-resolution formats (including SVG) ready for local print shops, eliminating the need for format conversion.
4. AI Photography That Elevates Sales
The platform transforms everyday snapshots into professional marketing assets. With a simple command like “turn this into a studio-quality product photo,” the AI enhances lighting, composition, and places products in realistic, on-brand environments. These high-quality visuals are optimized for Instagram, Google Maps, and digital displays, driving up to 41% higher engagement on product posts during early access.

Pricing and Availability
X-Design is available worldwide at https://www.x-design.com/. The platform offers:
1) Free Plan: Essential features for new businesses.
2) Pro Plan:Full AI access, unlimited brand assets, and high-res downloads.
3) Enterprise Plan: Custom solutions for larger teams.

About X-Design
X-Design empowers the heart of the local economy—small businesses—to compete visually with major chains. By combining generative AI with professional design principles, X-Design helps independent sellers create and apply cohesive visual identities across all touchpoints without the complexity or cost of traditional agencies.

Press & Partnership Contact
Email: info@x-design.com 
Website: https://www.x-design.com

INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

NANJING, China and GAITHERSBURG, Md., Dec. 4, 2025 /PRNewswire/ — TransThera Sciences Nanjing, Inc. (the “TransThera”) announced that Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation (“CDE”) of the National Medical Products Administration (“NMPA”) of the PRC, with the proposed indication for the treatment of adults with unresectable advanced or metastatic cholangiocarcinoma (CCA) who have received at least one prior systemic treatment and FGFR inhibitor treatment. Previously, Tinengotinib has been granted Breakthrough Therapy Designation by the NMPA for the treatment of CCA.

Disclaimer: This article serves as a press release by TransThera to disclose the company’s latest developments. It is not intended as a product promotion advertisement and does not constitute the company’s investment advice.

About Tinengotinib

Tinengotinib is an internally discovered, registrational clinical stage, multi-kinase inhibitor that exerts antitumor effects by targeting FGFRs/VEGFRs, Aurora kinases and Janus kinases (JAK).  Ongoing clinical trials in the US and China have revealed the potential of Tinengotinib to be efficacious in various solid tumors. It was granted the Orphan Drug Designation (ODD) and Fast Track Designation (FTD) by the FDA for the treatment of CCA, the Breakthrough Therapy Designation (BTD) by the NMPA in China, the Orphan Drug Designation (ODD) for the treatment of biliary tract cancer by the EMA.

About TransThera

TransThera is a clinical demand-oriented, registrational clinical-stage biopharmaceutical company focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. Further aided by in-depth study of translational medicine and drug design, TransThera aims to develop first-in-class or best-in-class drug candidates strategically positioned to meet urgent clinical needs on a global scale. For more information, please visit www.transthera.com 

Warmth in Action: Web3 & FinTech Industry’s Dual-Pronged Response to Hong Kong’s Tai Po Fire

HONG KONG, Dec. 4, 2025 /PRNewswire/ — Following the fire at Tai Po Hong Fuk Yuen on November 26, the Web3 and FinTech sectors swiftly mobilized, showcasing their social responsibility through an innovative aid model. Preliminary estimates indicate charitable donations from the industry have surpassed HKD 130 million, with funds prioritized for emergency relocation and community recovery. This response went beyond financial contributions, featuring the direct deployment of technical expertise and personnel, thereby injecting a sustainable “Tech for Good” momentum into traditional philanthropy.


Among the participating organizations, Vantage stood out by implementing a dual-track model combining financial donation with on-site deployment of a dedicated public welfare team. Working directly in the affected community to assist with relief distribution and resettlement support, the team translated the sector’s ethos of “warmth beyond code” into tangible action, demonstrating a new paradigm for Web3-powered public welfare. This integrated approach of capital and manpower not only enhanced aid efficiency but also illustrated how technology can act as a bridge connecting compassion with practical needs.

All charitable funds are now being coordinated and allocated by the relevant bodies. The collaborative multi-party effort highlights a profound integration of technological capability and humanistic spirit. As more organizations explore such innovative “online resources + offline action” pathways, disaster response mechanisms are poised to evolve toward greater efficiency and resilience.

 

Veeva AI Agents Now Available to Increase Productivity and Customer Centricity

Veeva AI delivers industry-specific AI for the next chapter in life sciences

SINGAPORE, Dec. 4, 2025 /PRNewswire/ — In a major milestone for Veeva AI, industry-specific AI for life sciences, Veeva Systems (NYSE: VEEV) today announced the availability of Veeva AI Agents for Vault CRM and PromoMats. Veeva AI in the Veeva Vault Platform and deep, specialized AI agents working in Veeva applications deliver practical AI with clear business value. Additional Veeva AI Agents for clinical, regulatory, safety, quality, medical, and commercial are planned for release throughout 2026.

“With industry-specific Veeva AI Agents working seamlessly in Veeva applications, the life sciences industry can increase productivity, customer centricity, and advance to new ways of working,” said Andy Han, senior vice president, Veeva AI. “Thanks to our customers for your collaboration as we rapidly develop practical AI that can have a significant impact on the industry.”

Veeva AI Now Available for Vault CRM

  • Free Text Agent detects and flags potential issues in call notes to ensure accuracy and compliance. With more in-depth call reporting, companies gain the advantage of richer, higher quality customer insights.
  • Voice Agent enables voice input for Vault CRM so it’s faster and easier for field teams to capture information and follow-up actions.
  • Pre-call Agent provides insights and suggested actions from relevant data, content, activity, and trends that help field reps prepare for calls.

Veeva AI Now Available for PromoMats

  • Quick Check Agent scans content using editorial, brand, market, channel, and compliance guidelines to address issues before medical, legal, regulatory (MLR) review.
  • Content Agent provides context-aware insights into document text and images, answers questions, summarizes content, analyzes visuals, and draws from Quick Check Agent to assist with document review.

Veeva AI Agents work seamlessly within Veeva applications and have direct, secure access to data, documents, and workflows and operate within established user access controls, permissions, and audit trails. Customers can also configure and extend Veeva-delivered AI Agents and build their own custom agents with Veeva AI.

Veeva Business Consulting provides support for the business process design and change management necessary as companies define new business and process flows among users and agents.

For the latest Veeva AI information, customers can visit the Veeva AI Community on Veeva Connect and join tomorrow’s Q&A to learn more about Veeva AI in Vault CRM.

What the Industry is Saying About Veeva AI

“By embedding AI into every step of the customer journey — from how practitioners receive valuable information about our portfolio to how they engage with our field force — Veeva AI is ideally positioned to support us in our mission to deliver life-changing medicines to patients worldwide.”

Greg Meyers, Executive Vice President, Chief Digital and Technology Officer
Bristol Myers Squibb

“What we’ve learned as an early access user is that the Veeva AI Quick Check Agent moves Moderna closer to a process where parts of MLR could become nearly touch-free. That’s the vision — and now we can genuinely see how we might get there.”

Jason Benagh, Global Marketing Operations Director
Moderna

“Vault CRM and Veeva AI Agents like Pre-call Agent and Voice Agent will drive efficiencies and allow the field to focus on the value parts of their jobs. It’s good for the business, good for HCPs, and great for patients.”

Frank Armenante, Director, Field Systems and Projects
Novo Nordisk

“Veeva is a critical system on our transformation roadmap, and it always has been. Being able to share the innovation with the leadership team and to introduce Veeva AI embedded into our Veeva applications is important to us as we expand our partnership.”

Debbie Young, Multichannel Strategy and Customer Insights Director
Otsuka Europe

“We’re excited to use the Veeva AI Free Text Agent as part of our strategy toward building AI capabilities into our business. Veeva AI enables us to gain deeper customer insights for more effective engagement in the rare disease space.”

– Kea Lingo, Chief Information Officer
Crinetics

“Accenture was an early Veeva AI Partner because we believe that Veeva’s unique industry-specific approach to AI will meaningfully increase productivity in life sciences. With our deep expertise in life sciences and proven ability to scale AI, we look forward to working together to ensure customers gain practical value from Veeva AI.”

Craig Robertson, Senior Managing Director, Life Sciences Americas
Accenture

“We expect Veeva AI Agents like Free Text Agent and Voice Agent will drive efficiency gains and insight capture that can have a transformative impact on how commercial teams operate into the future. EY is excited to support organizations on this journey toward next generation customer engagement.”

Silvano Perrotta, Partner, Life Sciences Digital Transformation
Ernst & Young AG

About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

Agoda Spotlights Central Asia as Rising Travel Destination for South Korean Travelers

SEOUL, South Korea, Dec. 4, 2025 /PRNewswire/ — With domestic and foreign airlines expanding flight options to Central Asia, the region is capturing the attention of South Korean travelers. Digital travel platform Agoda revealed that, based on accommodation searches made by South Korean travelers from January to October this year, search volume for four key Central Asian countries — Uzbekistan, Kazakhstan, Kyrgyzstan, and Tajikistan — has increased by 225% compared to the same period last year.

Uzbekistan

Famed as a central hub along the ancient Silk Road, Uzbekistan saw a 234% increase in searches by South Korean travelers this year. In particular, interest in Tashkent, the country’s capital, rose by 289% after T’way Air launched its direct Incheon–Tashkent route in May, marking it the first service to Uzbekistan by a Korean low-cost carrier. Meanwhile, the historic cities of Samarkand and Bukhara, both recognized as UNESCO World Heritage Sites, have also gained traction, with search volumes increasing by 127% and 59%, respectively.

Kazakhstan

With a 295% year-on-year increase in search volume among South Korean travelers, Kazakhstan is emerging as a new favorite destination in Central Asia. The launch of Eastar Jet’s new Incheon–Almaty route, which operated from April to October this year, boosted Almaty’s popularity, with search interest rising by 348%. Meanwhile, Shymkent, Kazakhstan’s third-largest city, has also gained popularity following SCAT Airlines’ launch of a direct flight from Incheon in May, resulting in an 89% increase in travel interest by South Koreans.

Kyrgyzstan

Often called the “Alps of Central Asia,” Kyrgyzstan has become a must-visit destination for adventure seekers, with search volume among South Korean travelers rising by 61% this year. Karakol and Cholpon-Ata — both located by Lake Issyk-Kul and renowned for their trekking routes and stunning natural landscapes — recorded 127% and 83% increases in searches, respectively. Bishkek, the capital of Kyrgyzstan, is also gaining popularity, with searches from South Korean travelers increasing by 46%.

Tajikistan

Tajikistan has seen a 43% rise in searches from South Korean travelers. In the capital city of Dushanbe, elegant European-style architecture lines the streets alongside bustling traditional bazaars, contributing to a 41% increase in search interest.

Jay Lee, Regional Director, North Asia at Agoda, said, “We’re seeing a clear rise in curiosity among South Korean travelers for destinations that combine adventure, culture, and authenticity, with Central Asia standing out as a region of growing interest. At Agoda, we’re excited to help travelers explore these emerging destinations and make planning their trips seamless with our wide range of flights, accommodations, and activities.”

Travelers looking for the perfect Central Asia trip can start their search on Agoda to select from over 6 million holiday properties, more than 130,000 flight routes, and over 300,000 activities, all easily combined in a single booking. Discover the best deals on Agoda’s mobile app and visit Agoda.com for more information.

Iinnofashion Leads Beauty Trends with Bubble-Type Toner Mask, Accelerating Its Rise as a Global Brand

SEOUL, South Korea, Dec. 4, 2025 /PRNewswire/ — Iinnofashion is presenting a new K-beauty trend powered by its distinctive technological expertise.

The recently launched “All-in-One Toner Mask Bubble Booster” stands out from conventional liquid toners with its innovative bubble formulation that delivers the effects of toner, mask, brightening, and soothing—all in a single use. Enriched with CICA extract, known for its exceptional calming properties, the product provides deep nourishment while functioning as a convenient yet highly effective mask pack for modern consumers seeking simplicity and results.

Iinnofashion is also pursuing a collaboration with Japan’s fashion brand ANAP, through which it plans to introduce a new lifestyle product lineup that merges fashion and beauty. In addition, the company is preparing to open a shop-in-shop store at Jeju’s Dongmun Market in November, expanding its offline sales channels targeting Chinese tourists.

A representative from Iinnofashion stated, “While bubble-type toner products are becoming more common, the ‘Bubble Booster’ distinguishes itself through its all-in-one concept and CICA-based soothing formula. We aim to establish ourselves as a brand that delivers the proven effectiveness and true value of K-beauty to global consumers.”

69% Global Executives Predict AI Agents will Reshape Business in 2026, According to DeepL Research

  • AI agents poised to drive enterprise-wide transformation in 2026
  • Regional divides revealed on AI adoption
  • Language and Voice AI become essential infrastructure for global operations

NEW YORK, Dec. 4, 2025 /PRNewswire/ — The age of the AI agent has arrived. New research from DeepL, a global AI product and research company, reveals that 2026 will mark a decisive shift from AI experimentation to agentic automation with a majority (69%) of global business leaders expecting agentic AI to transform their operations in the year ahead.

Surveying 5,000 executives across the United States, United Kingdom, France, Germany, and Japan, DeepL’s research finds that companies are preparing to deploy autonomous AI agents at scale to handle knowledge work, boost productivity, and reshape workforce structures – signaling what could be the most significant operational shift in business since the cloud.

“AI agents are no longer experimental, they are inevitable,” said Jarek Kutylowski, CEO and Founder of DeepL. “The next phase is embedding them deeply into how we work. In 2026, AI agents will end the grind of context-switching and repetitive tasks, letting people focus on what actually moves businesses forward.”

AI agents become the next enterprise disruptor

After early pilots and narrow use cases, AI agents are moving into enterprise production.

  • Nearly half (44%) of global business leaders expect major transformation from agentic AI in 2026, with another quarter (25%) saying it’s already underway. Only 7% believe AI agents will not change their operations, underscoring the speed of adoption.
  • Respondents reported that the top three drivers of confidence in AI agents include proven ROI and efficiency (22%), workforce adaptability (18%), and growing enterprise readiness (18%).
  • On the flip side, respondents cited the primary challenges with AI agent deployment as cost (16%), workforce preparedness (13%), and technology maturity (12%).

AI is the top growth driver for global business

Beyond AI agents, AI as a whole is now viewed as the primary engine of business growth for 2026.

  • Over two-thirds (67%) of respondents report rising ROI from their AI initiatives this year, and more than half (52%) expect AI to contribute more to company growth than any other technology next year.
  • The U.K. leads (80%) in measurable business performance from AI, followed by Germany (78%), the US (71%), and France (70%), while Japan lags at just 35%, suggesting slower adoption and readiness.
  • Interestingly, more than half (51%) of global business leaders believe AI will create more new roles next year than it replaces, and 52% say AI skills will be required for most new hires.

Language and voice AI evolve from tools to infrastructure

DeepL’s research also highlights how Language and Voice AI are becoming critical layers of enterprise infrastructure.

  • Nearly two-thirds (64%) of global businesses plan to increase investment in language AI in 2026 – led by the U.K. (76%), and followed by Germany (74%), the U.S. (67%), and France (65%) – as multilingual communication and content generation become core to cross-border growth. In contrast, Japan (38%) remains comparatively conservative, signaling slower momentum but still reflecting growing interest among more than one in three business leaders.

Voice AI, meanwhile, is shifting from “nice-to-have” to non-negotiable.

  • Over half (54%) of global business leaders say real-time voice translation will be essential in 2026, up from just one-third (32%) today.
  • The UK (48%) and France (33%) lead in early reliance on real-time voice translation tools, while Japan remains hesitant at just 11% relying on it today.
  • Demand is being driven by advances in live voice technology (46%), customer expectations (40%), and cross-market expansion (38%).

“Real-time voice translation is the next layer of global communication,” said Kutylowski. “When people can speak naturally and can be fully understood, collaboration accelerates.”

These insights can help arm global business leaders with critical insights into what’s coming next in AI, revealing how these shifts will reshape industries, redefine customer expectations, and ripple through the competitive landscape. To learn what DeepL’s executive team predicts for AI across technology, marketing, law, and more, please check out this blog post.

Methodology

This research was conducted by Censuswide on behalf of DeepL, surveying business leaders across the United States, United Kingdom, Germany, France, and Japan. The survey was conducted in September 2025. Censuswide abides by and employs members of the Market Research Society, which is based on the ESOMAR principles.

About DeepL

DeepL is a global AI product and research company focused on building secure, intelligent solutions to complex business problems. Over 200,000 business customers and millions of individuals across 228 global markets today trust DeepL’s Language AI platform for human-like translation, improved writing and real-time voice translation. Building on a history of innovation, quality and security, DeepL continues to expand its offerings beyond the field of Language, including DeepL Agent – an autonomous AI assistant designed to transform the way businesses and knowledge workers get work done. Founded in 2017 by CEO Jarek Kutylowski, DeepL now has over 1,000 passionate employees and is supported by world-renowned investors including Benchmark, IVP, and Index Ventures. For more information on DeepL, visit www.deepl.com.

Logo – https://laotiantimes.com/wp-content/uploads/2025/12/deepl_logo.jpg

High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology

SUZHOU, China, Dec. 4, 2025 /PRNewswire/ — On December 3, 2025 (local time in Arizona, USA), ImmVira Group (“ImmVira” or the “Company”) announced a poster presentation at the 26th Annual Meeting of the Society of Urologic Oncology (SUO 2025). The presentation featured the latest interim clinical data (as of September 19, 2025) for its lead HSV-1 oncolytic virus product. MVR-T3011, in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients.

The patients were enrolled and treated with intravesical MVR-T3011 at two dose levels: 2×109 PFU and 1×1010 PFU in this study. There were a total of 26 patients with papillary (16 patients at the dosage level of 2×109 PFU, 10 patients at the dosage level of 1×1010 PFU), and a total of 12 patients with carcinoma in situ (CIS) (7 patients at the dosage level of 2×109 PFU, 5 patients at the dosage level of 1×1010 PFU) enrolled in this trial. Data from the patients demonstrated a promising efficacy profile:

  • Among 16 evaluable patients with BCG-unresponsive papillary who received MVR-T3011 at a dose of 2×109 PFU, the 3-month, 6-month, 9-month and 12-month recurrence-free survival (RFS) rates were 87.1%, 80.4%, 80.4% and 71.4%, respectively. Among 6 evaluable patients who received MVR-T3011 at a dose of 1×1010 PFU, 100% of patients remained recurrence free at Month 3 and Month 6.

Source: The Company’s poster on 2025 SUO.
Source: The Company’s poster on 2025 SUO.

  • As of the same date, among 7 evaluable patients with BCG-unresponsive CIS (with or without Ta/T1) who received MVR-T3011 at doses of 2×109 PFU, the CR at any time, 3-month and 6-month CRR was 71.4%, and among 5 evaluable patients with BCG-unresponsive CIS (with or without Ta/T1) who received MVR-T3011 at doses of 1×1010 PFU, the CR at any time, 3-month and 6-month CRR was 100%.

Source: The Company’s poster on 2025 SUO.
Source: The Company’s poster on 2025 SUO.

Consistent with previous clinical findings, MVR-T3011 continued to demonstrate a favorable safety and tolerability profile in the latest study. Most treatment-emergent adverse events (TEAEs) were at Grades 1 or 2. Only five Grade 3 TEAEs were reported, two of which were treatment-related adverse events (TRAEs) and were consistent with reactions commonly associated with catheterization procedures. No Grade 3 or above TEAEs and no dose-limiting toxicities (DLT) occurred.

According to Frost & Sullivan, bladder cancer is one of the top 10 most common solid tumors globally by incidence and often requires prolonged treatment and surveillance spanning 5-10 years. NMIBC is a main type of bladder cancer, representing approximately 75% of all newly diagnosed bladder cancer cases. The current standard of care for high-risk NMIBC is Bacillus Calmette-Guerin (BCG). However, the availability of BCG is significantly limited by global supply shortages. In the U.S., BCG supply meets less than 30% of the total demand. These significant unmet medical needs highlight a clear opportunity for novel immunotherapies such as oncolytic viruses, which hold considerable potential as a new mechanism of action in this underserved market.

“We are highly encouraged by the interim efficacy data from the study, especially the high CR and RFS rate for both BCG-unresponsive CIS and papillary patients at 1×1010 PFU,” said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. “We have initiated a phase II trial for BCG-unresponsive high-risk NMIBC in the U.S. in June 2025 and are progressing a global multi-regional clinical trial (MRCT) inclusive of China. We believe MVR-T3011 could emerge as the new generation of therapy for patients with high-risk, BCG-unresponsive NMIBC.”

About MVR-T3011

MVR-T3011, represents a breakthrough in HSV-1-based oncolytic immunotherapy. Its proprietary “3-in-1” design unites a replication-competent, tumor-lytic HSV-1 backbone with anti-PD-(L)1 antibody and IL-12, enabling it simultaneously to lyse tumor cells and stimulate innate and adaptive immunity. MVR-T3011 has demonstrated its adaptability and feasibility across multiple routes of administration including intratumoral, intracavitary and intravenous administrations. MVR-T3011 is the world’s first HSV-1-based oncolytic immunotherapy that has completed a phase I trial via systemic intravenous dosing under the FDA regulatory regime.

About ImmVira

ImmVira is a global leading clinical-stage biotechnology company that is powered by proprietary biological engineering technology, and is dedicated to the discovery, development, manufacture and commercialization of novel oncolytic immunotherapies and engineered exosome therapies. We have strategically designed and built a risk-balanced product portfolio that comprised both potentially best-in-class oncolytic immunotherapy candidates for solid tumors and innovative engineered exosome assets for clinical application or direct commercialization. Driven by our strategic priority to become a global leader in the full spectrum of bladder cancer treatment development, we have adopted a rationalized, adaptive approach to advance oncolytic immunotherapy candidates with high clinical potential globally. In parallel, leveraging our deep expertise in biological engineering, we have pioneered development of engineered exosome candidates targeting chronic, hard-to-treat diseases as well as age-related conditions. These selected engineered exosome assets are being deliberately accelerated through strategic, differentiated regulatory pathways to enable expedited commercialization and generate sustainable cash flows that will fuel our broader drug development efforts.